Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dennis Xia
Observed name:
D. Xia
OpenAlex ID:
A5109525626
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
2023
·
Sophia Frentzas
, Hui K. Gan
, et al.
·
Cell Reports Medicine
·
45
Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events
2022
·
Zhaoliang Huang
, Xinghua Pang
, et al.
·
Frontiers in Immunology
·
44
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers
2022
·
Yulong Zheng
, Anna Rachelle Austria Mislang
, et al.
·
Cancer Immunology Immunotherapy
·
22
Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.
2021
·
Hui Kong Gan
, Jermaine Coward
, et al.
·
Journal of Clinical Oncology
·
18
289 Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone
2021
·
Zhaoliang Huang
, Xinghua Pang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
12
PDF
Abstract 5520: AK129, an anti-PD1/LAG-3 bi-specific antibody for cancer therapy
2022
·
Zhaoliang Huang
, Xinghua Pang
, et al.
·
Cancer Research
·
6
Abstract 5526: AK131, an anti-PD1/CD73 bispecific antibody for cancer immune therapy
2022
·
Zhaoliang Huang
, Xinghua Pang
, et al.
·
Cancer Research
·
6
Population Pharmacokinetic Modeling and Exposure-Response Analysis Providing a Basis for Selecting Penpulimab Dose in a Population with Relapsed/Refractory Classic Hodgkin's Lymphoma
2021
·
Benchao Chen
, Xiaopin Jin
, et al.
·
Blood
·
3
441 Population pharmacokinetics of an anti-PD-1 antibody, Penpulimab in patients with advanced malignancies
2021
·
Benchao Chen
, Xiaoping Jin
, et al.
·
Journal for ImmunoTherapy of Cancer
·
3
PDF
750 AK119, a CD73 targeting antibody with dual mechanism of action
2021
·
Zhaoliang Huang
, Xinghua Pang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
266 AK117, a CD47 blocking antibody with robust macrophage activation without red blood cell hemagglutination
2021
·
Zhaoliang Huang
, Xinghua Pang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
384 A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas
2020
·
Amy Prawira
, Jermaine Coward
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
157P Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
2020
·
A.R.A. Mislang
, J. Coward
, et al.
·
Annals of Oncology
·
2
Abstract 5524: AK127, a novel monoclonal antibody (mAb) targeting T cell immunoreceptor (TIGIT)
2022
·
Zhaoliang Huang
, Xinghua Pang
, et al.
·
Cancer Research
·
1
Abstract 3827: Bispecific antibodies with an anti-PD-1 backbone for cancer therapy generate enhanced immune activity
2018
·
Baiyong Li
, Zhaoliang Huang
, et al.
·
Cancer Research
·
1
Abstract 5422: Exploring the feasibility of longer dosing intervals in a population with relapsed/refractory classic Hodgkin's lymphoma based on population pharmacokinetics modeling analysis
2022
·
Benchao Chen
, Yongcheng Dong
, et al.
·
Cancer Research
31P Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma
2020
·
N. Xu
, B. Han
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
17
Citation count:
169
H-index:
6
I10-index:
5
Year
Topic
Type
